Lobefaro R, Viscardi G, Di Liello R, et al. - By examining data of patients with advanced non-small cell lung cancer (NSCLC) managed with immunotherapy in two Italian centers, researchers assessed how performance status (PS) (0-1 vs 2) could impact disease control rate (DCR), progression free survival (PFS) as well as overall survival (OS). There were 404 patients included in this study; among them, PS was 0 in 137 (33.9%), 1 in 208 (51.5%) and 2 in 59 (14.6%) patients. They noted that worse outcomes in terms of DCR, PFS and OS were experienced by patients with PS2 status. In univariate and multivariable analysis, PS2 status, negative programmed death ligand 1 expression, and early corticosteroids exposure, as well as higher neutrophil to lymphocyte ratio and LDH at baseline were identified to be related to worse results. Findings corroborated that despite good safety, lower efficacy with immunotherapy was seen in patients with poor PS. Although PS continues to be the most powerful independent prognostic factor for NSCLC, decision making in PS2 patients could be supported by LDH concentrations and steroids exposure.